Fulcrum Therapeutics, Inc. FULC R2KR3KPHARMA
Company Overview
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -43.80% |
| 6 Months: | -52.88% |
| 3 Months: | +4.34% |
| 1 Month: | +2.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 73.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FULC Fulcrum Therapeutics, Inc. R2KR3KPHARMA | 3.85 | -3.18 | $293.74M | 0.00% | -24.00% | -32.38% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 750.00K | 2.00M | 1.85M | 4.79M | 4.38M | 4.93M | 2.59M | 1.88M | 1.18M | 295.00K | 880.00K | 759.00K | 0 | 80.00M | 0 | - | 0 | 0 | - | - |
| Operating Income | - | -7.85M | -9.09M | -37.23M | -13.49M | -17.01M | -18.80M | -15.92M | -19.10M | -17.04M | -19.68M | -20.77M | -26.00M | -34.23M | -24.36M | -27.94M | -27.29M | -27.44M | -29.83M | 52.49M | -25.13M | -20.40M | -19.82M | -21.86M | -22.19M | -29.31M |
| Net Income | -6.94M | -7.85M | -8.94M | -36.84M | -13.17M | -16.54M | -18.45M | -15.69M | -18.96M | -17.00M | -19.65M | -20.72M | -25.93M | -34.07M | -23.74M | -24.78M | -23.78M | -24.02M | -26.87M | 55.41M | -21.70M | -17.66M | -17.30M | -19.59M | -18.89M | -26.18M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.60 | -0.57 | -0.64 | -0.83 | -0.51 | -0.41 | -0.38 | -0.39 | -0.43 | 0.87 | -0.35 | -0.28 | -0.28 | -0.31 | -0.25 | -0.34 |
| R&D Expense | - | 5.79M | 6.96M | 34.63M | 10.86M | 13.50M | 14.48M | 12.78M | 15.64M | 16.33M | 17.38M | 17.08M | 17.83M | 25.02M | 15.37M | 16.71M | 17.85M | 18.24M | 19.77M | 17.26M | 14.64M | 13.40M | 12.99M | 14.30M | 14.08M | 12.44M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 8.82M | 19.16M | 6.34M | 2.81M | 80.00M | 0 |
| Operating Income | -33.50M | -84.22M | -71.61M | -81.05M | -112.56M | -110.66M | -21.90M | -84.77M |
| Net Income | -32.59M | -82.68M | -70.82M | -80.85M | -109.87M | -97.33M | -9.72M | -74.88M |
| Diluted EPS | - | - | - | -2.29 | -2.44 | -1.59 | -0.16 | -1.18 |
| R&D Expense | 25.18M | 71.07M | 59.04M | 69.70M | 76.78M | 71.80M | 63.39M | 56.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 85.77M | 110.44M | 129.58M | 235.00M | 226.69M | 257.69M | 260.72M | 366.28M |
| Total Equity | -33.27M | -63.67M | 87.15M | 95.18M | 211.54M | 198.94M | 235.19M | 243.03M | 349.00M |
| Cash & Equivalents | - | 72.80M | 96.71M | 57.05M | 35.41M | 35.10M | 25.56M | 58.21M | 197.53M |
| Total Liabilities | - | 9.77M | 23.29M | 34.40M | 23.46M | 27.74M | 22.50M | 17.68M | 17.28M |
| Current Liabilities | - | 4.23M | 12.14M | 26.73M | 19.20M | 16.73M | 13.68M | 11.04M | 13.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.56M | -39.48M | -53.66M | - | -97.05M | -90.97M | -2.22M | -60.06M |
| Investing Cash Flow | -8.98M | -944.00K | -57.14M | - | 12.41M | -36.69M | 32.23M | 30.72M |
| Financing Cash Flow | 105.03M | 64.34M | 71.13M | - | 84.32M | 118.12M | 2.75M | 168.67M |
| Capital Expenditure | -8.98M | -853.00K | -1.34M | - | -1.96M | -508.00K | -278.00K | -314.00K |
| Free Cash Flow | -31.54M | -40.34M | -55.00M | - | -99.01M | -91.47M | -2.50M | -60.38M |
| Net Change in Cash | - | - | - | - | -314.00K | -9.54M | 32.76M | 139.32M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -811.6% | -423.0% | -1,774.9% | -3,945.2% | -27.4% | - |
| Net Margin % | - | - | -802.7% | -421.9% | -1,732.4% | -3,470.1% | -12.2% | - |
| ROE % | 51.2% | -94.9% | -74.4% | -38.2% | -55.2% | -41.4% | -4.0% | -21.5% |
| ROCE % | -41.1% | -85.7% | -69.6% | -37.6% | -53.6% | -45.4% | -8.8% | -24.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.57% | 8.82M | $33.97M |
| 2 | EcoR1 Capital, LLC | 8.58% | 6.55M | $25.22M |
| 3 | Tang Capital Management, LLC | 8.55% | 6.52M | $25.11M |
| 4 | Nantahala Capital Management, LLC | 7.18% | 5.48M | $21.08M |
| 5 | Montanova Capital LLC | 4.82% | 3.68M | $14.17M |
| 6 | Shaw D.E. & Co., Inc. | 3.99% | 3.04M | $11.72M |
| 7 | Vanguard Capital Management LLC | 3.54% | 2.70M | $10.38M |
| 8 | Citadel Advisors Llc | 3.54% | 2.70M | $10.41M |
| 9 | Jane Street Group, LLC | 2.91% | 2.22M | $8.54M |
| 10 | State Street Corporation | 2.67% | 2.04M | $7.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FULC
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPNU9ZREtILTYzVk54bzlLV1VwVk9FZzVIeDVhdlY5bUxIbkF3QVFGTGFET0NobDdUS2lxcFA4cllHY2RVSjRNdVQzMEdydnl1VWd1anRsc1o0YU1vaVotUTVZdmZKWEt0T2xxZTdRMnNadmYxM24wMGZLWHBIaFdQcTg2a3diRFZyajJ1VG…
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - daily-tribune.com
<a href="https://news.google.com/rss/articles/CBMiswJBVV95cUxOZlBiMmdzdi02Snlmblk2TXhtOXh1ZzNuMGpSQ2FzT0pTTTZjVXl2UFlYaTc4bnNDdG5FOHRjMHB4eGMyelpxaGc3d0ZyQ2JpeU1BRUJLV0FSS3A3dW1aUmZBd19RNlFLUGo5MDY4YWdSeWlmSFdPcE1wUUMwQ3NkcWlhb3BpM1BMdjRyMj…
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOTklDamVYWkh3UFBha25UZUpOUVNTZjFtbU9LZXVDMzFxZlpiaXdxSVNYTFd1eTBnejl6SDBkSENwRlZKakJCQUowazhHREdzYXN5SFQ2ZWlLakk0Y2FjN3R0U0tjRFpXaTdPQmt0T0Q1NnEyMHVJSHVLOEh6M1pGeGpPY1dtVEZ1VGlqRj…
Fulcrum to merge with Slate in all-stock deal after drug setback - Reuters
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOUnlRZk1yc3lpWTdfeDhYQjR0eEsyQWJiYjVyNGZkaFVzWU5KU0RPUWJUeEV3NHhsaHRzTnc1RGgyajg2NjdmQnRpMEtaTmpGajl3YnJlMndGdGhCMHlXMlFwdUlnSHM4STNnaXJmWjZMSnZsSFg1VVcwTFFwZVdsa181YUxNNUdvZ0dFRm…
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQaUwxMlpRQi1QSXdXbnBnczNPRjJJc0JIT2F2QnVqa1p1Z1hyQUhpWHFYRDRCZFdqMUdhUHRoRWdhQ2JJcGJVMDZPaUFVd2M5OEQyN2c0V24xZHdYaWJkcWZLSlN3VmJjRlRhVXdzMWo0SVpLU280M0xIdG0zWk1heFpZcnpaUmEzTGxpMn…
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPTnU2SDBHVFZOaVU0Z2FJTmQwSzR0WjNMSWRuSlZZMUlvZWR2UW5QcXc4WjdrdzdQS09PYzdkYTg5MUhMNDkxY0RGb2wxU05acU9WNE5mV1JPRjJMVGdMT3RGdEFrTUdCS2MySDBLTngtdVFYR3NSY1pCVVJoNDVvdmtEUVZVSW1CaXBQdk…
FULC — Frequently Asked Questions
What is the current share price of Fulcrum Therapeutics, Inc. (FULC)?
As of 2026-09-07 16:24 PDT, Fulcrum Therapeutics, Inc. (FULC) trades at $3.85 on NasdaqGM. Its 52-week range is $3.14 to $14.60.
What is the market capitalisation of FULC?
Fulcrum Therapeutics, Inc. (FULC) has a market capitalisation of $293.74M on NasdaqGM.
What is the P/E ratio of FULC?
FULC trades at a trailing price-to-earnings (P/E) ratio of -3.18. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.96.
What is the return on equity (ROE) of FULC?
FULC has a return on equity (ROE) of -32.38%. Its return on capital employed (ROCE) is -24.00%.
Is FULC a good stock to buy?
This page provides a data-driven analysis of Fulcrum Therapeutics, Inc. (FULC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.